All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-06-07T09:50:17.000Z

In the current AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?

Jun 7, 2023
Share:

Bookmark this article

The AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, In the current acute myeloid leukemia (AML) treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?

In the current AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?

Platzbecker begins by explaining that while both the symptoms of AML and treatment for AML can cause neutropenia, increasing patients’ susceptibility to bacterial or fungal infections, antibiotic prophylaxis is not normally recommended at this stage. He highlights the lack of randomized clinical trials investigating the use of general antibiotic prophylaxis in these patients, and differentiates this from neutropenic fever when antibiotic therapy is essential.

Platzbecker goes on to discuss antifungal prophylaxis, including a randomized clinical trial that has shown benefit of posaconazole compared with current standard of care, and how posaconazole prophylaxis is therefore recommended during intensive chemotherapy in patients with neutropenia. However, he highlights the cytochrome interactions necessitating dose reductions of venetoclax or ivosidenib when antifungal agents are given, and advises caution when using these combinations.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox